Ignite Creation Date:
2024-05-06 @ 8:20 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06344780
Status:
RECRUITING
Last Update Posted:
2024-04-03
First Post:
2024-03-28
Brief Title:
Abemaciclib Palbociclib or Dalpiciclib Combined With Endocrine Therapy as First-line Treatment in HR Positive HER2 Negative Unresectable or Metastatic Breast Cancer
Sponsor:
Organization:
Fudan University